Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea
Publication date: March 2018Source: Egyptian Journal of Basic and Applied Sciences, Volume 5, Issue 1Author(s): Islam Rady, Hadir Mohamed, Mohamad Rady, Imtiaz A. Siddiqui, Hasan MukhtarAbstract(-)-epigallocatechin-3-gallate (EGCG), the major bioactive catechin in green tea (GT) has been studied for almost past thirty years as an agent initially for its cancer chemoprevention effects and then for its cancer chemotherapeutic ability. This agent has shown considerable anti-cancer effects in a variety of preclinical cell culture and animal model systems. However, its clinical application to human patients is hampered by a variety of reasons that includes its stability and bioavailability. As a result, an increased number of studies assessing the effects derived from the use of EGCG are been employed in combination with other agents or by utilizing innovative carrier settings. Here, we summarize the current understanding of the anticancer effects of EGCG and its effects with other combinations on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of EGCG.
Publication date: Available online 11 July 2020Source: European UrologyAuthor(s): Roderick C.N. van den Bergh, Olivier Rouvière, Theodorus van der Kwast, Erik Briers, Thomas Van den Broeck, Philip Cornford, Marcus G. Cumberbatch, Maria De Santis, Stefano Fanti, Nicola Fossati, Giorgio Gandaglia, Nikolaos Grivas, Jeremy Grummet, Thomas B. Lam, Michael Lardas, Matthew Liew, Lisa Moris, Malcolm D. Mason, Nicolas Mottet, Daniela E. Oprea-Lager
Publication date: Available online 11 July 2020Source: European Journal of Surgical OncologyAuthor(s): Xin Chen, Xingyu Feng, Muqing Wang, Xueqing Yao
Publication date: Available online 10 July 2020Source: Pathology - Research and PracticeAuthor(s): Yiyang Bai, Jia Hou, Xiao Wang, Luying Geng, Xiaohui Jia, Luochengling Xiang, Kejun Nan
Publication date: Available online 10 July 2020Source: Gynecologic Oncology ReportsAuthor(s): McKayla J. Riggs, Miranda Lin, Joseph Kim, Prakash Pandalai, Charles Dietrich
Publication date: Available online 10 July 2020Source: Nutrition, Metabolism and Cardiovascular DiseasesAuthor(s): Caterina Bonfiglio, Carla Maria Leone, Liciana Vaz de Arruda Silveira, Rocco Guerra, Giovanni Misciagna, Maria Gabriella Caruso, Irene Bruno, Claudia Buongiorno, Angelo Campanella, Vito Maria Bernardo Guerra, Maria Notarnicola, Valentina Deflorio, Isabella Franco, Antonella Bianco, Antonella Mirizzi, Laura Rosana Aballay, Anna Maria Cisternino, Paolo Sorino, Pasqua Letizia Pesole, Alberto Rubén Osella
Publication date: Available online 11 July 2020Source: Medical Journal Armed Forces IndiaAuthor(s): Nikita Naredi, Pankaj Talwar, Sandeep Karunakaran
In this study, 1452 patients were enrolled. Independent risk factors for recurrence-free survival (RFS) and overall survival (OS) were analyzed for patients with and without CSPH. For HCC patients without CSPH, multivariate analysis suggested that microvascular invasion (MVI), neutrophil-to-lymphocyte ratio (NLR) ≥ 3, platelet-to-lymphocyte ratio (PLR) ≥ 150, tumor size> 5 cm, and the presence of a satellite lesion were independently associated with RFS. MVI, NLR ≥ 3, PLR ≥ 150, and advanced Barcelona clinical liver cancer (BCLC) stage contributed to mortality. However, neither NLR nor PLR showed any prognos...
LUNG cancer symptoms include difficulty breathing, headaches, and persistent chest pain. But you could also be at risk of a tumour if you notice a subtle change to your voice. This is the warning sign of lung cancer you should be looking out for when you speak.
Publication date: Available online 10 July 2020Source: Cancer EpidemiologyAuthor(s): K. Waddell, M. Matua, C. Bidwell, R. Atwine, J. Onyango, S.V. Picton, I. Simmons, J. Stahlschmidt, W.T. Johnston, R. Newton
Conclusion: HRR is a new prognostic factor that can be used to predict PFS/OS in MIBC. PMID: 32648774 [PubMed - as supplied by publisher]